By stratifying patients according to MGMT methylation status, clinicians can optimize therapeutic regimens, minimize treatment-related toxicity, and improve outcomes for glioblastoma patients, particularly in cases where resistance is suspected [101]. The gene discussed is MGMT; the disease is glioblastoma.